Ep. 275 NMIBC Tumor Board: Nuances in Management with Dr. Mark Tyson and Dr. Sarah Psutka
Description
When standard therapy fails, it does not have to be the end of the road for high-risk bladder cancer patients. Modern treatments, biomarkers, and clinical studies have opened up new avenues for treating recurrent non-muscle invasive bladder cancer (NMIBC). The penultimate episode of the 2025 NMIBC Creator Weekend™ series features urologic oncologists Dr. Vignesh Packiam, Dr. Mark Tyson, and Dr. Sarah Psutka discussing how they navigate complex bladder cancer scenarios.
---
This podcast is supported by:
Ferring Pharmaceuticals
https://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1
---
SYNPOSIS
The doctors share treatment strategies, staging processes, and post-therapy patient management techniques. They address recurrent disease, approaches to different stages of cancer, the role of biomarkers in determining treatment paths, and considerations for both high-risk and intermediate-risk patients. Additionally, the episode touches on new treatments, clinical trials, and patient quality of life post-treatment.
---
TIMESTAMPS
00:00 - Introduction
02:08 - Case Study: Initial Patient Assessment
04:59 - Surgical Considerations and Techniques
10:22 - Managing Bladder Cancer Recurrence
11:15 - Treatment Options and Clinical Trials
15:12 - Advanced Treatment Strategies
28:14 - Closing Remarks and Credits
---
RESOURCES
VISTA Trial https://abstracts.mirrorsmed.org/abstracts/vista-phase-3-trial-vicinium-epcam-targeted-pseudomonas-exotoxin-bcg-unresponsive-non
BRIDGE Trial
https://pmc.ncbi.nlm.nih.gov/articles/PMC10515442/
CORE-008 Trial
https://www.sciencedirect.com/science/article/abs/pii/S1078143924010147
GAIN Trial
https://pmc.ncbi.nlm.nih.gov/articles/PMC10176900/
United States
